{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:28:55Z","timestamp":1792790935364,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"French Ministry of Health (PHRC) Societe fran\u00e7aise de Rhumatologie","id":[{"id":"https:\/\/ror.org\/04g47ec58","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    About 10\u201320% of patients with Kawasaki disease (KD) are unresponsive to intravenous immunoglobulin (IVIg) and are at increased risk of coronary artery abnormalities (CAAs). Early identification is critical to initiate aggressive therapies, but available scoring systems lack sensitivity in non-Japanese populations. We investigated the accuracy of 3 Japanese scoring systems and studied factors associated with IVIg unresponsiveness in a large multiethnic French population of children with KD to build a new scoring system. Children admitted for KD between 2011\u20132014 in 65 centers were enrolled. Factors associated with second line-treatment; i.e. unresponsiveness to initial IVIg treatment, were analyzed by multivariate regression analysis. The performance of our score and the Kobayashi, Egami and Sano scores were compared in our population and in ethnic subgroups. Overall, 465 children were reported by 84 physicians; 425 were classified with KD (55% European Caucasian, 12% North African\/Middle Eastern, 10% African\/Afro-Caribbean, 3% Asian and 11% mixed). Eighty patients (23%) needed second-line treatment. Japanese scores had poor performance in our whole population (sensitivity 14\u201361%). On multivariate regression analysis, predictors of secondary treatment after initial IVIG were hepatomegaly, ALT level \u226530 IU\/L, lymphocyte count &lt;2400\/mm\n                    <jats:sup>3<\/jats:sup>\n                    and time to treatment &lt;5 days. The best sensitivity (77%) and specificity (60%) of this model was with 1 point per variable and cut-off \u22652 points. The sensitivity remained good in our 3 main ethnic subgroups (74\u201388%). We identified predictors of IVIg resistance and built a new score with good sensitivity and acceptable specificity in a non-Asian population.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-59972-7","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T06:03:17Z","timestamp":1582178597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease"],"prefix":"10.1038","volume":"10","author":[{"given":"Maryam","family":"Piram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Darce Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Tellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Boralevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-5272","authenticated-orcid":false,"given":"Fouad","family":"Madhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Meinzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Cimaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Piedvache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Kon\u00e9-Paut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"59972_CR1","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","volume":"135","author":"BW McCrindle","year":"2017","unstructured":"McCrindle, B. W. et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 135, e927\u2013e999 (2017).","journal-title":"Circulation"},{"key":"59972_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/1756-185X.13219","volume":"21","author":"A Dionne","year":"2017","unstructured":"Dionne, A. & Dahdah, N. Myocarditis and Kawasaki disease. Int. J. rheumatic Dis. 21, 45\u201349 (2017).","journal-title":"Int. J. rheumatic Dis."},{"key":"59972_CR3","doi-asserted-by":"publisher","first-page":"e1695","DOI":"10.1542\/peds.2014-0004","volume":"134","author":"C Tissandier","year":"2014","unstructured":"Tissandier, C. et al. Kawasaki shock syndrome complicating a recurrence of Kawasaki disease. Pediatrics 134, e1695\u20131699 (2014).","journal-title":"Pediatrics"},{"key":"59972_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.semarthrit.2014.07.007","volume":"44","author":"W Wang","year":"2015","unstructured":"Wang, W., Gong, F., Zhu, W., Fu, S. & Zhang, Q. Macrophage activation syndrome in Kawasaki disease: more common than we thought? Semin. arthritis rheumatism 44, 405\u2013410 (2015).","journal-title":"Semin. arthritis rheumatism"},{"key":"59972_CR5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0140-6736(84)91504-6","volume":"2","author":"K Furusho","year":"1984","unstructured":"Furusho, K. et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 2, 1055\u20131058 (1984).","journal-title":"Lancet"},{"key":"59972_CR6","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S0022-3476(97)70038-6","volume":"131","author":"M Terai","year":"1997","unstructured":"Terai, M. & Shulman, S. T. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J. pediatrics 131, 888\u2013893 (1997).","journal-title":"J. pediatrics"},{"key":"59972_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3109\/s10165-004-0324-3","volume":"14","author":"M Mori","year":"2004","unstructured":"Mori, M. et al. Meta-analysis of the results of intravenous gamma globulin treatment of coronary artery lesions in Kawasaki disease. Mod. Rheumatol. 14, 361\u2013366 (2004).","journal-title":"Mod. Rheumatol."},{"key":"59972_CR8","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1136\/archdischild-2018-315087","volume":"104","author":"RMR Tulloh","year":"2018","unstructured":"Tulloh, R. M. R. et al. Kawasaki disease: a prospective population survey in the UK and Ireland from 2013 to 2015. Arch. Dis. Child. 104, 640\u2013646 (2018).","journal-title":"Arch. Dis. Child."},{"key":"59972_CR9","doi-asserted-by":"publisher","first-page":"E78","DOI":"10.1542\/peds.105.6.e78","volume":"105","author":"CA Wallace","year":"2000","unstructured":"Wallace, C. A., French, J. W., Kahn, S. J. & Sherry, D. D. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 105, E78 (2000).","journal-title":"Pediatrics"},{"key":"59972_CR10","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/S0140-6736(11)61930-2","volume":"379","author":"T Kobayashi","year":"2012","unstructured":"Kobayashi, T. et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 379, 1613\u20131620 (2012).","journal-title":"Lancet"},{"key":"59972_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/archdischild-2012-302841","volume":"99","author":"D Eleftheriou","year":"2014","unstructured":"Eleftheriou, D. et al. Management of Kawasaki disease. Arch. Dis. Child. 99, 74\u201383 (2014).","journal-title":"Arch. Dis. Child."},{"key":"59972_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jpeds.2006.03.050","volume":"149","author":"K Egami","year":"2006","unstructured":"Egami, K. et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J. pediatrics 149, 237\u2013240 (2006).","journal-title":"J. pediatrics"},{"key":"59972_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00431-006-0223-z","volume":"166","author":"T Sano","year":"2007","unstructured":"Sano, T. et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur. J. pediatrics 166, 131\u2013137 (2007).","journal-title":"Eur. J. pediatrics"},{"key":"59972_CR14","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1161\/CIRCULATIONAHA.105.592865","volume":"113","author":"T Kobayashi","year":"2006","unstructured":"Kobayashi, T. et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113, 2606\u20132612 (2006).","journal-title":"Circulation"},{"key":"59972_CR15","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jpeds.2010.10.031","volume":"158","author":"LA Sleeper","year":"2011","unstructured":"Sleeper, L. A. et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J. pediatrics 158, 831\u2013835 (2011).","journal-title":"J. pediatrics"},{"key":"59972_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jpeds.2007.12.021","volume":"153","author":"AH Tremoulet","year":"2008","unstructured":"Tremoulet, A. H. et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J. pediatrics 153, 117\u2013121 (2008).","journal-title":"J. pediatrics"},{"key":"59972_CR17","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00296-016-3499-y","volume":"36","author":"J Sanchez-Manubens","year":"2016","unstructured":"Sanchez-Manubens, J. et al. Role of the Egami score to predict immunoglobulin resistance in Kawasaki disease among a Western Mediterranean population. Rheumatol. Int. 36, 905\u2013910 (2016).","journal-title":"Rheumatol. Int."},{"key":"59972_CR18","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1136\/archdischild-2014-307397","volume":"100","author":"S Davies","year":"2015","unstructured":"Davies, S. et al. Predicting IVIG resistance in UK Kawasaki disease. Arch. Dis. Child. 100, 366\u2013368 (2015).","journal-title":"Arch. Dis. Child."},{"key":"59972_CR19","doi-asserted-by":"publisher","first-page":"e0215665","DOI":"10.1371\/journal.pone.0215665","volume":"14","author":"E Fernandez-Cooke","year":"2019","unstructured":"Fernandez-Cooke, E. et al. Epidemiological and clinical features of Kawasaki disease in Spain over 5 years and risk factors for aneurysm development. (2011\u20132016): KAWA-RACE study group. PLoS One 14, e0215665 (2019).","journal-title":"PLoS One"},{"key":"59972_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jpeds.2016.12.018","volume":"184","author":"R Song","year":"2017","unstructured":"Song, R., Yao, W. & Li, X. Efficacy of Four Scoring Systems in Predicting Intravenous Immunoglobulin Resistance in Children with Kawasaki Disease in a Children\u2019s Hospital in Beijing, North China. J. pediatrics 184, 120\u2013124 (2017).","journal-title":"J. pediatrics"},{"key":"59972_CR21","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.3346\/jkms.2017.32.12.1991","volume":"32","author":"J Shin","year":"2017","unstructured":"Shin, J., Lee, H. & Eun, L. Verification of Current Risk Scores for Kawasaki Disease in Korean Children. J. Korean Med. Sci. 32, 1991\u20131996 (2017).","journal-title":"J. Korean Med. Sci."},{"key":"59972_CR22","doi-asserted-by":"crossref","unstructured":"Bar-Meir, M. et al. Prediction of Resistance to Intravenous Immunoglobulin in Children With Kawasaki Disease. Journal of the Pediatric Infectious Diseases Society (2017).","DOI":"10.1093\/jpids\/piw075"},{"key":"59972_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ijcard.2016.03.017","volume":"214","author":"T Kibata","year":"2016","unstructured":"Kibata, T. et al. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin. Int. J. cardiology 214, 209\u2013215 (2016).","journal-title":"Int. J. cardiology"},{"key":"59972_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/ped.12317","volume":"56","author":"Research Committee of the Japanese Society of Pediatric, C. & Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki, D.","year":"2014","unstructured":"Research Committee of the Japanese Society of Pediatric, C. & Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki, D. Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version). Pediatr. Int. 56, 135\u2013158 (2014).","journal-title":"Pediatr. Int."},{"key":"59972_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12969-018-0301-6","volume":"16","author":"JS Baek","year":"2018","unstructured":"Baek, J. S. et al. Coronary artery status of patients with transient fever 24\u201336 h after first IVIG infusion did not differ from that seen in responsive patients. Pediatr. Rheumatol. Online J. 16, 83 (2018).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"59972_CR26","unstructured":"Research Committee on Kawasaki disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo, Japan, Ministry of Health and Welfare. (1994)."},{"key":"59972_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/INF.0b013e3181f386db","volume":"30","author":"M Seki","year":"2011","unstructured":"Seki, M. et al. External validation of a risk score to predict intravenous immunoglobulin resistance in patients with kawasaki disease. Pediatric Infect. Dis. J. 30, 145\u2013147 (2011).","journal-title":"Pediatric Infect. Dis. J."},{"issue":"695\u2013699","key":"59972_CR28","first-page":"e691","volume":"155","author":"T Heuclin","year":"2009","unstructured":"Heuclin, T. et al. Increased detection rate of Kawasaki disease using new diagnostic algorithm, including early use of echocardiography. J. pediatrics 155(695\u2013699), e691 (2009).","journal-title":"J. pediatrics"},{"issue":"501","key":"59972_CR29","first-page":"e501","volume":"69","author":"S Bayers","year":"2013","unstructured":"Bayers, S., Shulman, S. T. & Paller, A. S. Kawasaki disease: part I. Diagnosis, clinical features, and pathogenesis. J. Am. Acad. Dermatol. 69(501), e501\u2013511 (2013).","journal-title":"J. Am. Acad. Dermatol."},{"key":"59972_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13052-016-0306-z","volume":"42","author":"MC Maggio","year":"2016","unstructured":"Maggio, M. C., Corsello, G., Prinzi, E. & Cimaz, R. Kawasaki disease in Sicily: clinical description and markers of disease severity. Ital. J. Pediatr. 42, 92 (2016).","journal-title":"Ital. J. Pediatr."},{"key":"59972_CR31","doi-asserted-by":"publisher","first-page":"e1009","DOI":"10.1542\/peds.2013-2936","volume":"133","author":"J Saundankar","year":"2014","unstructured":"Saundankar, J. et al. The epidemiology and clinical features of Kawasaki disease in Australia. Pediatrics 133, e1009\u20131014 (2014).","journal-title":"Pediatrics"},{"key":"59972_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJM198608073150601","volume":"315","author":"JW Newburger","year":"1986","unstructured":"Newburger, J. W. et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N. Engl. J. Med. 315, 341\u2013347 (1986).","journal-title":"N. Engl. J. Med."},{"key":"59972_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12969-018-0264-7","volume":"16","author":"D Chbeir","year":"2018","unstructured":"Chbeir, D. et al. Kawasaki disease: abnormal initial echocardiogram is associated with resistance to IV Ig and development of coronary artery lesions. Pediatr. Rheumatol. Online J. 16, 48 (2018).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"59972_CR34","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00246-005-0916-5","volume":"26","author":"AR Porcalla","year":"2005","unstructured":"Porcalla, A. R., Sable, C. A., Patel, K. M., Martin, G. R. & Singh, N. The epidemiology of Kawasaki disease in an urban hospital: does African American race protect against coronary artery aneurysms? Pediatr. Cardiol. 26, 775\u2013781 (2005).","journal-title":"Pediatr. Cardiol."},{"key":"59972_CR35","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1097\/INF.0000000000002019","volume":"37","author":"DE Clark","year":"2018","unstructured":"Clark, D. E. et al. Predictors of Intravenous Immunoglobulin Nonresponse and Racial Disparities in Kawasaki Disease. Pediatric Infect. Dis. J. 37, 1227\u20131234 (2018).","journal-title":"Pediatric Infect. Dis. J."},{"key":"59972_CR36","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/ijms17030278","volume":"17","author":"D Rigante","year":"2016","unstructured":"Rigante, D. et al. Critical Overview of the Risk Scoring Systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome. Int. J. Mol. Sci. 17, 278 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"59972_CR37","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1542\/peds.2011-0148","volume":"129","author":"S Ogata","year":"2012","unstructured":"Ogata, S. et al. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics 129, e17\u201323 (2012).","journal-title":"Pediatrics"},{"key":"59972_CR38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5603\/KP.a2016.0179","volume":"75","author":"E Berdej-Szczot","year":"2017","unstructured":"Berdej-Szczot, E. et al. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease. Kardiol. Pol. 75, 261\u2013266 (2017).","journal-title":"Kardiol. Pol."},{"key":"59972_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12969-017-0149-1","volume":"15","author":"T Xie","year":"2017","unstructured":"Xie, T. et al. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease. Pediatr. Rheumatol. Online J. 15, 17 (2017).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"59972_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10238-018-00544-5","volume":"19","author":"Y Wu","year":"2019","unstructured":"Wu, Y. et al. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm. Clin. Exp. Med. 19, 173\u2013181 (2019).","journal-title":"Clin. Exp. Med."},{"key":"59972_CR41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/JAHA.116.005378","volume":"6","author":"MBF Son","year":"2017","unstructured":"Son, M. B. F. et al. Predicting Coronary Artery Aneurysms in Kawasaki Disease at a North American Center: An Assessment of Baseline z Scores. J. Am. Heart Assoc. 6, 6 (2017).","journal-title":"J. Am. Heart Assoc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59972-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59972-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59972-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T02:19:44Z","timestamp":1670293184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-59972-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["59972"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-59972-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,20]]},"assertion":[{"value":"2 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3125"}}